M
Michael V. Knopp
Researcher at The Ohio State University Wexner Medical Center
Publications - 471
Citations - 20059
Michael V. Knopp is an academic researcher from The Ohio State University Wexner Medical Center. The author has contributed to research in topics: Magnetic resonance imaging & Positron emission tomography. The author has an hindex of 68, co-authored 460 publications receiving 18728 citations. Previous affiliations of Michael V. Knopp include German Cancer Research Center & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.
Paul S. Tofts,Gunnar Brix,David L. Buckley,Jeffrey L. Evelhoch,Elizabeth Henderson,Michael V. Knopp,Henrik Larsson,Ting-Yim Lee,Nina A. Mayr,Geoffrey J. M. Parker,Ruediger E. Port,June S. Taylor,Robert M. Weisskoff +12 more
TL;DR: A standard set of quantity names and symbols related to the estimation of kinetic parameters from dynamic contrast‐enhanced T1‐weighted magnetic resonance imaging data, using diffusable agents such as gadopentetate dimeglumine (Gd‐DTPA), are described.
Journal ArticleDOI
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Richard T. Kloos,Matthew D. Ringel,Michael V. Knopp,Nathan Hall,Mark A. King,Robert Stevens,Jiachao Liang,Paul E. Wakely,Vasyl Vasko,Motoyasu Saji,Jennifer Rittenberry,Lai Wei,Daria Arbogast,Minden Collamore,John J. Wright,Michael R. Grever,Manisha H. Shah +16 more
TL;DR: Sorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC and four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylated, ERK phosphorylation, and in VEGF expression during sorafenIB therapy.
Journal ArticleDOI
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
Martin O. Leach,Kevin M. Brindle,Jeffrey L. Evelhoch,John R. Griffiths,Michael R. Horsman,Alan Jackson,Gordon C Jayson,Ian Judson,Michael V. Knopp,R. J. Maxwell,D McIntyre,Anwar R. Padhani,Patricia M Price,R Rathbone,Gordon J. S. Rustin,Paul S. Tofts,Gillian M. Tozer,W Vennart,John C. Waterton,Stephen R. Williams,Paul Workman +20 more
TL;DR: The outcome of a workshop that considered the methodology and design of magnetic resonance studies is reported, recommending how this new tool might best be used.
Journal ArticleDOI
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Benjamin M. Ellingson,Martin Bendszus,Martin Bendszus,Jerrold L. Boxerman,Daniel P. Barboriak,Bradley J. Erickson,Marion Smits,Marion Smits,Sarah J. Nelson,Elizabeth R. Gerstner,Elizabeth R. Gerstner,Brian M. Alexander,Gregory V. Goldmacher,Wolfgang Wick,Wolfgang Wick,Michael A. Vogelbaum,Michael A. Vogelbaum,Michael Weller,Evanthia Galanis,Jayashree Kalpathy-Cramer,Lalitha K. Shankar,Paula M. Jacobs,Whitney B. Pope,Dewen Yang,Caroline Chung,Michael V. Knopp,Soonme Cha,Martin J. van den Bent,Martin J. van den Bent,Susan M. Chang,W. K. Alfred Yung,Timothy F. Cloughesy,Patrick Y. Wen,Mark R. Gilbert,Mark R. Gilbert,Andrew Whitney,David Sandak,Al Musella,Chas Haynes,Max Wallace,David Arons,Ann E Kingston +41 more
TL;DR: The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials.
Journal ArticleDOI
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
TL;DR: Current research focuses on improving understanding of the meaning of DCE‐MRI at a molecular level, evaluating macromolecular and targeted contrast agents, and combining DCE-MRI with other physiologic imaging techniques such as positron emission tomography.